激光杂志
激光雜誌
격광잡지
LASER JOURNAL
2014年
1期
66-68
,共3页
加兰他敏%阿尔兹海默病
加蘭他敏%阿爾玆海默病
가란타민%아이자해묵병
galantamine%Alzheimer ’ s disease
目的:采用循证医学的方法评价加兰他敏治疗阿尔茨海默病(Alzheimer ’s disease, AD)效果。方法:检索国内外发表的有关加兰他敏治疗阿尔茨海默病的随机对照试验(RCTs)文献,采用Meta分析方法,利用RevMan5.0软件评价加兰他敏的疗效。计算合并均数差(MD)和相对危险度(RR)值,95%置信区间(CI),及不良反应发生率。结果:最终纳入11篇RCTs。分析结果显示:在认知能力方面,加兰他敏对AD的MMSE量表评分在治疗后提高(MD=2.04,95%CI:0.77,3.31),在基线分数基础上,ADAS-Cog积分评分下降,有积极作用(MD=-3.20,95%CI:-3.60,-2.80);在生活能力上,加兰他敏对AD的ADL量表评分无明显影响(MD=0.25,95%CI:-1.10,1.60),在DAD量表评分上经加兰他敏治疗后有所提高(MD=4.06,95%CI:3.83,4.28);在行为能力上,加兰他敏对 AD 的 NPI 量表评分下降(MD=-1.36,95%CI:-2.21,-0.52);AD患者经加兰他敏治疗对CIBIC-plus分数改变有着积极的作用。不良反应呕吐发生率最高,但对腹泻无明显影响作用。结论:加兰他敏对AD患者在认知、生活能力、行为能力和CIBIC-plus分数改变有一定治疗效果,但仍需更充分的证据。
目的:採用循證醫學的方法評價加蘭他敏治療阿爾茨海默病(Alzheimer ’s disease, AD)效果。方法:檢索國內外髮錶的有關加蘭他敏治療阿爾茨海默病的隨機對照試驗(RCTs)文獻,採用Meta分析方法,利用RevMan5.0軟件評價加蘭他敏的療效。計算閤併均數差(MD)和相對危險度(RR)值,95%置信區間(CI),及不良反應髮生率。結果:最終納入11篇RCTs。分析結果顯示:在認知能力方麵,加蘭他敏對AD的MMSE量錶評分在治療後提高(MD=2.04,95%CI:0.77,3.31),在基線分數基礎上,ADAS-Cog積分評分下降,有積極作用(MD=-3.20,95%CI:-3.60,-2.80);在生活能力上,加蘭他敏對AD的ADL量錶評分無明顯影響(MD=0.25,95%CI:-1.10,1.60),在DAD量錶評分上經加蘭他敏治療後有所提高(MD=4.06,95%CI:3.83,4.28);在行為能力上,加蘭他敏對 AD 的 NPI 量錶評分下降(MD=-1.36,95%CI:-2.21,-0.52);AD患者經加蘭他敏治療對CIBIC-plus分數改變有著積極的作用。不良反應嘔吐髮生率最高,但對腹瀉無明顯影響作用。結論:加蘭他敏對AD患者在認知、生活能力、行為能力和CIBIC-plus分數改變有一定治療效果,但仍需更充分的證據。
목적:채용순증의학적방법평개가란타민치료아이자해묵병(Alzheimer ’s disease, AD)효과。방법:검색국내외발표적유관가란타민치료아이자해묵병적수궤대조시험(RCTs)문헌,채용Meta분석방법,이용RevMan5.0연건평개가란타민적료효。계산합병균수차(MD)화상대위험도(RR)치,95%치신구간(CI),급불량반응발생솔。결과:최종납입11편RCTs。분석결과현시:재인지능력방면,가란타민대AD적MMSE량표평분재치료후제고(MD=2.04,95%CI:0.77,3.31),재기선분수기출상,ADAS-Cog적분평분하강,유적겁작용(MD=-3.20,95%CI:-3.60,-2.80);재생활능력상,가란타민대AD적ADL량표평분무명현영향(MD=0.25,95%CI:-1.10,1.60),재DAD량표평분상경가란타민치료후유소제고(MD=4.06,95%CI:3.83,4.28);재행위능력상,가란타민대 AD 적 NPI 량표평분하강(MD=-1.36,95%CI:-2.21,-0.52);AD환자경가란타민치료대CIBIC-plus분수개변유착적겁적작용。불량반응구토발생솔최고,단대복사무명현영향작용。결론:가란타민대AD환자재인지、생활능력、행위능력화CIBIC-plus분수개변유일정치료효과,단잉수경충분적증거。
Objective To evaluate the efficacy of galantamine in the treatment of Alzheimer's disease. Methods Randomized controlled trials (RCTs) on galantamine treatment of Alzheimer's disease were re-trieved by searching international and national databases. The pooled mean difference and relative risk and 95% CI were assessed by Meta analysis with RevMan 5.0 software. Results 11 RCTs were included. Cognition: the results of meta-analysis showed that the value of MMSE was significantly higher in AD group (MD=2.04,95%CI:0.77,3.31), ADAS-Cog change from baseline to endpoint was lower (MD=-3.20,95%CI:-3.60,-2.80) for galantamine in AD group. Function: the pooled mean difference was of ADL (MD=0.25, 95%CI:-1.10,1.60) for galantamine in AD, the pooled mean difference of DAD was (MD=4.06,95%CI:3.83, 4.28) . Behavior: The value of NPI was significantly lower for galantamine in AD (MD=-1.36,95%CI:-2.21-0.52) .CIBIC-Plus score: positive change after galantamine treatment in AD group. Conclusion Slightly more efficacious changes are in the cognitive, function, behavioral and CIBIC-plus scores for Galantamine in AD. More eligibility trials are needed for providing more evidences.